Veronica Obregon-Perko

Dr. Veronica Obregon-Perko


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KBKatherine Bricker
Katherine Bricker
VOVeronica Obregon-Perko
Veronica Obregon-Perko
FUFerzan Uddin
Ferzan Uddin
BWBrianna Williams
Brianna Williams
EREmilie Russell
Emilie Russell
ACAnn Chahroudi
Ann Chahroudi
Globally, 1.8 million children are living with HIV-1. While antiretroviral therapy (ART) has improved disease outcomes, it does not eliminate the latent HIV-1 reservoir. Interventions to delay or prevent viral rebound in the absence of ART would be highly beneficial for HIV-1-infected children who now must remain on daily ART throughout their lifespan. Here, we evaluated therapeutic Ad48-SIV prime, MVA-SIV boost immunization in combination with the TLR-7 agonist GS-986 in rhesus macaque (RM) infants orally infected with SIVmac251at 4 weeks of age and treated with a triple ART regimen beginning 4 weeks after infection. We hypothesized immunization would enhance SIV-specific T cell responses during ART-mediated suppression of viremia. Compared to controls, vaccinated infants had greater magnitude SIV-specific T cell responses (mean of 3475 vs 69 IFN-γspot forming cells (SFC) per 106PBMCs, respectively, P = 0.01) with enhanced breadth of epitope recognition and increased CD8+and CD4+T cell polyfunctionality (P = 0.004 and P = 0.005, respectively). Additionally, SIV-specific gp120 antibodies against challenge and vaccine virus strains were significantly elevated following MVA boost (P = 0.02 and P < 0.001, respectively). GS-986 led to expected immune stimulation demonstrated by activation of monocytes and T cells 24 hours post-dose. Despite the vaccine-induced immune responses, levels of SIV DNA in peripheral and lymph node CD4+T cells were not significantly different from controls and a similar time to viral rebound and viral load set point were observed following ART interruption in both groups. We demonstrate infant RMs mount a robust immunological response to this immunization, but vaccination alone was not sufficient to impact viral reservoir size or modulate rebound dynamics following ART release. Our findings hold promise for therapeutic vaccination as a part of a combination cure approach in children and highlight the importance of a pediatric model to evaluate HIV-1 cure interventions in this unique setting of immune development.

8 December 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
VOVeronica Obregon-Perko
Veronica Obregon-Perko
KBKatherine Bricker
Katherine Bricker
GMGloria Mensah
Gloria Mensah
FUFerzan Uddin
Ferzan Uddin
LRLaura Rotolo
Laura Rotolo
ACAnn Chahroudi
Ann Chahroudi
Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission. We thus investigated viral rebound after analytical treatment interruption (ATI) in 10 infant macaques orally infected with SHIV.C.CH505 and treated with long-term ART. Rebound viremia was detected within 7 to 35 days of ATI in 9 of 10 animals, with posttreatment control of viremia seen in 5 of 5 Mamu-A*01 + macaques. Single-genome sequencing revealed that initial rebound virus was similar to viral DNA present in CD4 + T cells from blood, rectum, and lymph nodes before ATI. We assessed the earliest sites of viral reactivation immediately following ATI using ImmunoPET imaging. The largest increase in signal that preceded detectable viral RNA in plasma was found in the gastrointestinal (GI) tract, a site with relatively high SHIV RNA/DNA ratios in CD4 + T cells before ATI. Thus, the GI tract may be an initial source of rebound virus, but as ATI progresses, viral reactivation in other tissues likely contributes to the composition of plasma virus. Our study provides potentially novel insight into the features of viral rebound in pediatric infection and highlights the application of a noninvasive technique to monitor areas of HIV-1 expression in children.

22 February 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
VSVidisha Singh
Vidisha Singh
VOVeronica Obregon-Perko
Veronica Obregon-Perko
SLStacey A. Lapp
Stacey A. Lapp
AHAnna Marie Horner
Anna Marie Horner
ABAlyssa Brooks
Alyssa Brooks
ACAnn Chahroudi
Ann Chahroudi
Why multisystem inflammatory syndrome in children (MIS-C) develops after SARS-CoV-2 infection in a subset of children is unknown. We hypothesized that aberrant virus–specific T cell responses contribute to MIS-C pathogenesis. We quantified SARS-CoV-2–reactive T cells, serologic responses against major viral proteins, and cytokine responses from plasma and peripheral blood mononuclear cells in children with convalescent COVID-19, in children with acute MIS-C, and in healthy controls. Children with MIS-C had significantly lower virus-specific CD4 + and CD8 + T cell responses to major SARS-CoV-2 antigens compared with children convalescing from COVID-19. Furthermore, T cell responses in participants with MIS-C were similar to or lower than those in healthy controls. Serologic responses against spike receptor binding domain (RBD), full-length spike, and nucleocapsid were similar among convalescent COVID-19 and MIS-C, suggesting functional B cell responses. Cytokine profiling demonstrated predominant Th1 polarization of CD4 + T cells from children with convalescent COVID-19 and MIS-C, although cytokine production was reduced in MIS-C. Our findings support a role for constrained induction of anti–SARS-CoV-2–specific T cells in the pathogenesis of MIS-C.

27 June 2024 in Epidemics
Verified
Journal Article
Open access
EMEllie Mainou
Ellie Mainou
SBStella J. Berendam
Stella J. Berendam
VOVeronica Obregon-Perko
Veronica Obregon-Perko
EUEmilie A. Uffman
Emilie A. Uffman
CPCaroline T. Phan
Caroline T. Phan
CCCliburn Chan
Cliburn Chan
While the benefits of early antiretroviral therapy (ART) initiation in perinatally infected infants are well documented, early initiation is not always possible in postnatal pediatric HIV infections. The timing of ART initiation is likely to affect the size of the latent viral reservoir established, as well as the development of adaptive immune responses, such as the generation of neutralizing antibody responses against the virus. How these parameters impact the ability of infants to control viremia and the time to viral rebound after ART interruption is unclear and has never been modeled in infants. To investigate this question we used an infant nonhuman primate Simian/Human Immunodeficiency Virus (SHIV) infection model. Infant Rhesus macaques (RMs) were orally challenged with SHIV.C.CH505 375H dCT and either given ART at 4-7 days post-infection (early ART condition), at 2 weeks post-infection (intermediate ART condition), or at 8 weeks post-infection (late ART condition). These infants were then monitored for up to 60 months post-infection with serial viral load and immune measurements. To gain insight into early after analytic treatment interruption (ATI), we constructed mathematical models to investigate the effect of time of ART initiation in delaying viral rebound when treatment is interrupted, focusing on the relative contributions of latent reservoir size and autologous virus neutralizing antibody responses. We developed a stochastic mathematical model to investigate the joint effect of latent reservoir size, the autologous neutralizing antibody potency, and CD4+ T cell levels on the time to viral rebound for RMs rebounding up to 60 days post-ATI. We find that the latent reservoir size is an important determinant in explaining time to viral rebound in infant macaques by affecting the growth rate of the virus. The presence of neutralizing antibodies can also delay rebound, but we find this effect for high potency antibody responses only. Finally, we discuss the therapeutic implications of our findings.

29 October 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
VOVeronica Obregon-Perko
Veronica Obregon-Perko
AAAchal Awasthi
Achal Awasthi
RBRichard Barfield
Richard Barfield
SBStella Joan Berendam
Stella Joan Berendam
BYBhrugu Yagnik
Bhrugu Yagnik
ACAnn Chahroudi
Ann Chahroudi
Evaluation of HIV cure strategies requires antiretroviral therapy (ART) interruption, but ethical and clinical considerations make this difficult in children. Here, we used a pediatric preclinical model of simian-HIV (SHIV) infection to uncover features associated with time to viral rebound (TTR) and posttreatment control (PTC) of rebound viremia after ART interruption to inform the design of studies testing cure interventions. We assessed 141 variables in SHIV-infected infant rhesus macaques in three staggered ART initiation groups and during subsequent analytical treatment interruption (ATI). Viral rebound occurred in 25 of 30 macaques within 7 to 98 days of ATI, with TTR delayed in the early ART group compared with the intermediate and late ART groups. Peak plasma viral load pre-ART was the most important correlate of TTR, with increased model performance through the successive inclusion of six additional viral and immune variables. The odds of PTC were reduced with higher SHIV RNA in rectal CD4 + T cells pre-ATI; conversely, higher frequencies of Ki67 + effector memory CD8 + T cells in lymph nodes increased the likelihood of PTC. RNA sequencing of CD4 + T cells pre-ATI revealed a down-regulated metabolic and immune gene signature in macaques with PTC. Analysis of the early ART group alone implicated transforming growth factor–β signaling genes in lack of viral rebound off ART. This comprehensive investigation reveals major determinants of viral rebound dynamics after ART interruption that should be validated and explored as potential biomarkers to screen children with HIV being considered for ATI.

22 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EMEllie Mainou
Ellie Mainou
SBStella Joan Berendam
Stella Joan Berendam
VOVeronica Obregon-Perko
Veronica Obregon-Perko
EREmilie Russell
Emilie Russell
CPCaroline T Phan
Caroline T Phan
CCCliburn Chan
Cliburn Chan
A bstract: While the benefits of early antiretroviral therapy (ART) initiation in perinatally infected infants are well documented, early ART initiation is not always possible in postnatal pediatric HIV infections, which account for the majority of pediatric HIV cases worldwide. The timing of onset of ART initiation is likely to affect the size of the latent viral reservoir established, as well as the development of adaptive immune responses, such as the generation of neutralizing antibody responses against the virus. How these parameters impact the ability of infants to control viremia and the time to viral rebound after ART interruption is unclear. To gain insight into the dynamics, we utilized mathematical models to investigate the effect of time of ART initiation via latent reservoir size and autologous virus neutralizing antibody responses in delaying viral rebound when treatment is interrupted. We used an infant nonhuman primate Simian/Human Immunodeficiency Virus (SHIV) infection model that mimics breast milk HIV transmission in human infants. Infant Rhesus macaques (RMs) were orally challenged with SHIV.C.CH505 375H dCT and either given ART at 4-7 days post-infection (early ART condition), at 2 weeks post-infection (intermediate ART condition), or at 8 weeks post-infection (late ART condition). These infants were then monitored for up to 60 months post-infection with serial viral load and immune measurements. We develop a stochastic mathematical model to investigate the joint effect of latent reservoir size, the autologous neutralizing antibody potency, and CD4+ T cell levels on the time to viral rebound and control of post-rebound viral loads. We find that the latent reservoir size is an important determinant in explaining time to viral rebound by affecting the growth rate of the virus. The presence of neutralizing antibodies also can delay rebound, but we find this effect for high potency antibody responses only.